Literature DB >> 36253445

The NQO1/p53/SREBP1 axis promotes hepatocellular carcinoma progression and metastasis by regulating Snail stability.

Xinyue Wang1,2, Ying Liu1, Anna Han1, Chunxiao Tang1, Ran Xu1, Linyuan Feng1,2, Yang Yang1,2, Liyan Chen1, Zhenhua Lin3,4.   

Abstract

Hepatocellular carcinoma (HCC) is the second leading cause of cancer-related mortality worldwide, and its abnormal metabolism affects the survival and prognosis of patients. Recent studies have found that NAD(P)H quinone oxidoreductase-1 (NQO1) played an important role in tumor metabolism and malignant progression. However, the molecular mechanisms by which NQO1 regulates lipid metabolism during HCC progression remain unclear. In this study, bioinformatics analysis and immunohistochemical results showed that NQO1 was highly expressed in HCC tissues and its high expression was closely related to the poor prognosis of HCC patients. Overexpression of NQO1 promoted the cell proliferation, epithelial-to-mesenchymal transition (EMT) process, and angiogenesis of HCC cells. Luciferase reporter assay further revealed that NQO1/p53 could induce the transcriptional activity of SREBP1, consequently regulating HCC progression through lipid anabolism. In addition, Snail protein was stabilized by NQO1/p53/SREBP1 axis and triggered the EMT process, and participated in the regulatory role of NQO1/p53/SREBP1 axis in HCC. Together, these data indicated that NQO1/SREBP1 axis promoted the progression and metastasis of HCC, and might be a potential therapeutic target for HCC.
© 2022. The Author(s), under exclusive licence to Springer Nature Limited.

Entities:  

Year:  2022        PMID: 36253445     DOI: 10.1038/s41388-022-02477-6

Source DB:  PubMed          Journal:  Oncogene        ISSN: 0950-9232            Impact factor:   8.756


  45 in total

1.  A Regulatory Role of Apoptosis Antagonizing Transcription Factor in the Pathogenesis of Nonalcoholic Fatty Liver Disease and Hepatocellular Carcinoma.

Authors:  Divya P Kumar; Prasanna K Santhekadur; Mulugeta Seneshaw; Faridoddin Mirshahi; Cora Uram-Tuculescu; Arun J Sanyal
Journal:  Hepatology       Date:  2019-03-04       Impact factor: 17.425

2.  The gluconeogenic enzyme PCK1 phosphorylates INSIG1/2 for lipogenesis.

Authors:  Daqian Xu; Zheng Wang; Yan Xia; Fei Shao; Weiya Xia; Yongkun Wei; Xinjian Li; Xu Qian; Jong-Ho Lee; Linyong Du; Yanhua Zheng; Guishuai Lv; Jia-Shiun Leu; Hongyang Wang; Dongming Xing; Tingbo Liang; Mien-Chie Hung; Zhimin Lu
Journal:  Nature       Date:  2020-04-08       Impact factor: 49.962

3.  The CREB coactivator CRTC2 controls hepatic lipid metabolism by regulating SREBP1.

Authors:  Jinbo Han; Erwei Li; Liqun Chen; Yuanyuan Zhang; Fangchao Wei; Jieyuan Liu; Haiteng Deng; Yiguo Wang
Journal:  Nature       Date:  2015-07-06       Impact factor: 49.962

4.  O-GlcNAcylation of RACK1 promotes hepatocellular carcinogenesis.

Authors:  Fangfang Duan; Hao Wu; Dongwei Jia; Weicheng Wu; Shifang Ren; Lan Wang; Shushu Song; Xinying Guo; Fenglin Liu; Yuanyuan Ruan; Jianxin Gu
Journal:  J Hepatol       Date:  2018-02-15       Impact factor: 25.083

Review 5.  Epidemiology and surveillance for hepatocellular carcinoma: New trends.

Authors:  Amit G Singal; Pietro Lampertico; Pierre Nahon
Journal:  J Hepatol       Date:  2020-02       Impact factor: 25.083

Review 6.  Metabolic rearrangements in primary liver cancers: cause and consequences.

Authors:  Letizia Satriano; Monika Lewinska; Pedro M Rodrigues; Jesus M Banales; Jesper B Andersen
Journal:  Nat Rev Gastroenterol Hepatol       Date:  2019-10-30       Impact factor: 46.802

7.  Targeting metastasis-initiating cells through the fatty acid receptor CD36.

Authors:  Gloria Pascual; Alexandra Avgustinova; Stefania Mejetta; Mercè Martín; Andrés Castellanos; Camille Stephan-Otto Attolini; Antoni Berenguer; Neus Prats; Agustí Toll; Juan Antonio Hueto; Coro Bescós; Luciano Di Croce; Salvador Aznar Benitah
Journal:  Nature       Date:  2016-12-07       Impact factor: 49.962

Review 8.  Locoregional therapies in the era of molecular and immune treatments for hepatocellular carcinoma.

Authors:  Josep M Llovet; Thierry De Baere; Laura Kulik; Philipp K Haber; Tim F Greten; Tim Meyer; Riccardo Lencioni
Journal:  Nat Rev Gastroenterol Hepatol       Date:  2021-01-28       Impact factor: 46.802

9.  TIP30 regulates lipid metabolism in hepatocellular carcinoma by regulating SREBP1 through the Akt/mTOR signaling pathway.

Authors:  F Yin; G Sharen; F Yuan; Y Peng; R Chen; X Zhou; H Wei; B Li; W Jing; J Zhao
Journal:  Oncogenesis       Date:  2017-06-12       Impact factor: 7.485

Review 10.  Strategies to Improve the Antitumor Effect of Immunotherapy for Hepatocellular Carcinoma.

Authors:  Rui Xing; Jinping Gao; Qi Cui; Qian Wang
Journal:  Front Immunol       Date:  2021-11-26       Impact factor: 7.561

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.